Imaging in Drug Discovery and Early Clinical Trials

  • Paul L. Herrling
  • Alex Matter
  • Markus Rudin

Part of the Progress in Drug Research book series (PDR, volume 62)

Table of contents

  1. Front Matter
    Pages i-x
  2. Paul L. Herrling
    Pages 1-14
  3. David Sosnovik, Ralph Weissleder
    Pages 83-115
  4. Olivier Gheysens, Sanjiv S. Gambhir
    Pages 117-150
  5. R. Mark Henkelman, X. Josette Chen, John G. Sled
    Pages 151-184
  6. Markus Rudin, Nicolau Beckmann, Martin Rausch
    Pages 185-255
  7. Mats Bergström, Bengt Långström
    Pages 279-317
  8. Back Matter
    Pages 385-392

About this book


The impact of genomics on biomedical research and the development of efficient technology platforms allowing for highly parallel compound synthesis and screening procedures have led to a major paradigm shift in drug discovery and development. Efficient tools for the selection and validation of drug targets both at the preclinical and clinical level are required. Non-invasive imaging and in particular molecular imaging methods are becoming essential technologies to support drug discovery and dvelopment. Imaging provides structural, functional, metabolic and molecular readouts that are being applied to characterize a disease phenotype (diagnosis), to elucidate molecular mechanisms involved, to evaluate drug efficacy and safety, and to identify potential biomarkers of the drug's mechanism-of-action, efficacy and safety. Non-invasive imaging techniques constitute a bridge between preclinical and clinical drug evaluation.
In this monograph the contribution of imaging modalities to the various stages of drug discovery and development, from early target validation to their use in clinical development programs, is described. Chapters are devoted to the description of the drug discovery process as such, to the various imaging modalities being used both preclinically and clinically, to applications of imaging during the optimization of a lead compound (addressing issues such as bioavailability and efficacy) and during the drug safety evaluation. A chapter describes imaging biomarkers, their development, advantages and the potential pitfalls associated with their use. In the translation of imaging tools from animals to man regulatory issues have to be addressed, which are dealt with in a separate section.
The monograph provides a comprehensive overview on the role of imaging in drug discovery today and discusses major developments and trends both with regard to technologies and applications.


Drug Discovery Imaging Trend fluorescence lead optimization

Editors and affiliations

  • Paul L. Herrling
    • 2
  • Alex Matter
    • 3
  • Markus Rudin
    • 1
  1. 1.Institute for Biomedical EngineeringUniversity of Zürich/ETH ZürichZürichSwitzerland
  2. 2.Novartis International AGBaselSwitzerland
  3. 3.Novartis Institute for Tropical DiseasesSingaporeSingapore

Bibliographic information